CARDIOR PHARMACEUTICALS
Cardior Pharmaceuticals is a biotechnology company that engages in the development of non-coding RNA based therapeutics for the treatment and prevention of heart disease. It focuses on developing CDR-132X, an oligonucleotide-based inhibitor of a molecular master switch (microRNA) controlling pathological alterations of the heart following stress or injury. Cardior Pharmaceuticals is a planned academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of death in the western world.
CARDIOR PHARMACEUTICALS
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2016-01-01
Address:
Hanover, Niedersachsen, Germany
Country:
Germany
Website Url:
http://www.cardior.de
Total Employee:
11+
Status:
Active
Contact:
+49 (0)511-33 85 99 30
Email Addresses:
[email protected]
Total Funding:
80.01 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Nginx Sitelinks Search Box Yoast WordPress SEO Plugin Yoast SEO Premium
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Current Advisors List
Current Employees Featured
Founder
Investors List
BioMedPartners
BioMedPartners investment in Series B - Cardior Pharmaceuticals
Inkef
Inkef investment in Series B - Cardior Pharmaceuticals
Life Sciences Partners
Life Sciences Partners investment in Series B - Cardior Pharmaceuticals
Sunstone Partners
Sunstone Partners investment in Series B - Cardior Pharmaceuticals
Hadean Ventures
Hadean Ventures investment in Series B - Cardior Pharmaceuticals
High-Tech Grunderfonds
High-Tech Grunderfonds investment in Series B - Cardior Pharmaceuticals
Fund+
Fund+ investment in Series B - Cardior Pharmaceuticals
Bristol Myers Squibb
Bristol Myers Squibb investment in Series B - Cardior Pharmaceuticals
coparion
coparion investment in Series B - Cardior Pharmaceuticals
European regional development fund (ERDF)
European regional development fund (ERDF) investment in Grant - Cardior Pharmaceuticals
Official Site Inspections
http://www.cardior.de
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Cardior Pharmaceuticals"
Our Core - Cardior
Steffen has been supporting Cardior’s assets since 2017 and guided the lead compound from non-clinical to successful clinical Phase 1b completion and beyond. Before he joined Cardior …See details»
News & Events - Cardior
Cardior’s lead candidate CDR132L is featured in the article “Non-coding RNAs in disease: from mechanisms to therapeutics” published in Nature Reviews Genetics on November 15, 2023. The article by Kinga Nemeth, Recep Bayraktar, …See details»
Cardior Pharmaceuticals - Crunchbase Company Profile …
Cardior Pharmaceuticals is a biotechnology company that engages in the development of non-coding RNA based therapeutics for the treatment and …See details»
Cardior Pharmaceuticals - Wikitia
Cardior.de: Cardior Pharmaceuticals GmbH is a clinical-stage biopharmaceutical company based in Hanover Germany founded in 2016. The company is developing curative and preventive …See details»
Cardior Pharmaceuticals (Cardior Pharmaceuticals …
Cardior: Deutsches BioTech um 1 Milliarde Euro an Novo Nordisk verkauft Wenn BioTech aufgeht, dann ganz groß: Soeben hat der dänische Pharma-Riese Novo Nordisk, in den letzten Jahren für seine Abnehmspritzen berühmt geworden, …See details»
Cardior Pharmaceuticals GmbH - Hannover - praxis-dr-gehring.de
Cardior Pharmaceuticals GmbH ist ein renommiertes Biotechnologieunternehmen mit Fokus auf die Entwicklung innovativer Therapeutika für Herz-Kreislauf-Erkrankungen. Die Adresse des …See details»
CARDIOR • life science startup | HTGF
CARDIOR is a Hannover-based life science startup Part of the #HTGFFamily since 2017 Read more. ... [email protected] Web: www.cardior.de. Address. Cardior Pharmaceuticals …See details»
At the pulse of heart diseases - Cardior
Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to ... [email protected] Phone …See details»
Cardior Pharmaceuticals GmbH - Implisense
Entdecken Sie die Cardior Pharmaceuticals GmbH auf Implisense, dem B2B-Portal für Firmeninformationen. Profil, Kontaktdaten, News - alles auf einen Blick! Kostenlos registrieren; …See details»
EQT Life Sciences’ portfolio company Cardior Pharmaceuticals to …
Mar 25, 2024 Cardior is a leader in RNA-targeted therapies for people with cardiovascular diseases EQT Life Sciences is the company’s largest shareholder and has backed Cardior’s …See details»
Wilfried Hauke - CMO at Cardior - The Org
CMO at Cardior. Contact. Dr. Wilfried Hauke is a physician by training specialized in pharmaceutical medicine. With more than 30 years of working in various fields of the …See details»
#rna #heartfailure | Cardior Pharmaceuticals - LinkedIn
Read more about the announcement in our new "media" section on the website highlighting select media coverage here: https://cardior.de/media/ Or the full press release here: …See details»
Cardior Pharmaceuticals | VentureRadar
Similar Companies: HAYA Therapeutics Switzerland Publicly Traded HAYA Therapeutics is a Swiss-based pre-clinical early stage biopharmaceutical company currently developing a first-in …See details»
Media - Cardior
Our recent transformative announcement was broadly covered in international media and industry publications highlighting the potential of our lead candidate CDR132L in heart failure and …See details»
Novo Nordisk targets heart disease in $1.1 billion deal
Mar 25, 2024 Novo Nordisk said it's paying up to 1.02 billion euros ($1.1 billion) for Cardior Pharmaceuticals, a German company developing therapies that target RNA to prevent and …See details»
BIO Deutschland und Cardior zu Gast bei der Medizinisch-Nat…
Auf Einladung der Medizinisch-Naturwissenschaftlichen Gesellschaft Wuppertal e.V. (MNG) hielt BIO Deutschland-Geschäftsführerin Viola Bronsema einen Vortrag im Rahmen der …See details»
Compliance - Cardior
We take compliance seriously at Cardior As part of our commitment to maintaining the highest standards, we have integrated with Novo Nordisk’s robust compliance management system. …See details»
Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA ...
Cardior is currently initiating a Phase II clinical trial of the antisense drug. About Cardior . Cardior Pharmaceuticals is a leading clinical -stage biopharmaceutical company pioneering the …See details»
Our Approach - Cardior
Our goal at Cardior is to identify and counteract the molecular mechanisms of the broad area of ischemic-induced heart failure as well as specific cardiac diseases such as hypertrophic and …See details»